{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Huan X"],"funding":["Shanghai Municipal Hospital Development Center","National Natural Science Foundation of China","National Key Research and Development Program of China"],"pagination":["e70513"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12836041"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(2)"],"pubmed_abstract":["<h4>Background</h4>Myasthenic crisis (MC) affects 10%-20% of myasthenia gravis patients and is life-threatening with significant economic burden, yet its long-term outcomes remain poorly understood. This prospective multicentre study aimed to evaluate 1-year clinical outcomes after MC.<h4>Methods</h4>This study enrolled patients with MC between December 2018 and October 2024 and prospectively followed at 1, 2, 3, 6, and 12 months post-MC. Outcome measures included Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) classification at 1 year after MC, all-cause mortality, and complications.<h4>Results</h4>The cohort comprised 277 patients with 282 MC episodes with a follow-up duration of 29.16 ± 15.93 months. The in-hospital mortality was 5.05% (14/277), while the al"],"journal":["European journal of neurology"],"pubmed_title":["1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China."],"pmcid":["PMC12836041"],"funding_grant_id":["82471426","2022YFC3501305","2022YFC3501303","SHDC2023CRD007"],"pubmed_authors":["Ruan Z","Zhang H","Jiang Q","Bu B","Deng H","Zheng J","Liu Y","Xi J","Zou Z","Jia W","Wang Y","Wu W","Chen R","Xi C","Zhou H","Jin L","Yang H","Yang L","Zhao C","Huan X","Chinese Myasthenia Gravis Collaborating Group (CMGCG)","Chang T","Yang C","Song J","Li W","Li Y","Guan Y","Da Y","Luo L","Duan R","Tan S","Zhong H","Yan C","Shi J","Luo S","Yang S","Yue Y","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.","description":"<h4>Background</h4>Myasthenic crisis (MC) affects 10%-20% of myasthenia gravis patients and is life-threatening with significant economic burden, yet its long-term outcomes remain poorly understood. This prospective multicentre study aimed to evaluate 1-year clinical outcomes after MC.<h4>Methods</h4>This study enrolled patients with MC between December 2018 and October 2024 and prospectively followed at 1, 2, 3, 6, and 12 months post-MC. Outcome measures included Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) classification at 1 year after MC, all-cause mortality, and complications.<h4>Results</h4>The cohort comprised 277 patients with 282 MC episodes with a follow-up duration of 29.16 ± 15.93 months. The in-hospital mortality was 5.05% (14/277), while the al","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-06-14T03:13:01.018Z","creation":"2026-06-14T03:08:52.132Z"},"accession":"S-EPMC12836041","cross_references":{"pubmed":["41589418"],"doi":["10.1111/ene.70513"]}}